Search

Your search keyword '"Ferrand, Hélène"' showing total 12 results
Start Over Author "Ferrand, Hélène"
12 results on '"Ferrand, Hélène"'

1. Time to treatment initiation and HIV viral suppression in people diagnosed with HIV-1 during COVID-19 pandemic in ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study)

Author

Ben Farhat, Jihane, primary, Hessamfar, Mojgan, additional, Farbos, Sophie, additional, Desclaux, Arnaud, additional, Dumondin, Gilles, additional, Ferrand, Hélène, additional, Greib, Carine, additional, Castan, Bernard, additional, Rispal, Patrick, additional, Duffau, Pierre, additional, Leleux, Olivier, additional, Perrier, Adélaïde, additional, Wittkop, Linda, additional, Bonnet, Fabrice, additional, and Barger, Diana, additional

Published
2023
Full Text
View/download PDF

3. Incidence of lung and HPV-associated malignancies in HIV-infected patients

Author

Le-Marec, Fabien, Chaussade, Hélène, Coureau, Gaëlle, Leleux, Olivier, Neau, Didier, Lazaro, Estibaliz, Amadeo, Brice, Duffau, Pierre, Ferrand, Hélène, Courtault, Carine, Foucan, Anne-Sophie, Wittkop, Linda, Bonnet, Fabrice, Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2021
Full Text
View/download PDF

4. Incidence of lung and human papilloma virus-associated malignancies in HIV-infected patients

Author

Chaussade, Hélène, primary, Le Marec, Fabien, additional, Coureau, Gaëlle, additional, Leleux, Olivier, additional, Neau, Didier, additional, Lazaro, Estibaliz, additional, Amadeo, Brice, additional, Duffau, Pierre, additional, Ferrand, Hélène, additional, Courtault, Carine, additional, Foucan, Anne-Sophie, additional, Wittkop, Linda, additional, and Bonnet, Fabrice, additional

Published
2021
Full Text
View/download PDF

5. Liste des collaborateurs

Author

Affres, Hélène, primary, Amar, Laurence, additional, Amate, Pascale, additional, Annane, Djillali, additional, Azria, Elie, additional, Benachi, Alexandra, additional, Berlin, Ivan, additional, Bernuau, Jacques, additional, Bobrie, Guillaume, additional, Boleslawski, Emmanel, additional, Bonneau, Claire, additional, Bornes, Marie, additional, Bouhnik, Yoram, additional, Bouteloup, Corinne, additional, Bouvet, Elisabeth, additional, Brémond-Gignac, Dominique, additional, Bresset, Arnaud, additional, Bretelle, Florence, additional, Bricaire, Léopoldine, additional, Bruyere, Marie, additional, Ceccaldi, Pierre-François, additional, Chanson, Philippe, additional, Chauvet, Sophie, additional, Clair, Bernard, additional, Clouqueur, Élodie, additional, Cohen, Sarah, additional, Conard, Jacqueline, additional, Comarmond, Cloé, additional, Conquy, Sophie, additional, Copin, Henri, additional, Cordier, Anne-Gaël, additional, Cordiez, Sophie, additional, Costedoat-Chalumeau, Nathalie, additional, Daraï, Emile, additional, Delabaere, Amélie, additional, Deruelle, Philippe, additional, Dommergues, Marc, additional, Dreyfus, Marie, additional, Dubertret, Caroline, additional, Du-Boutin, Lê Thi Huong, additional, Ducarme, Guillaume, additional, Ducloy-Bouthors, Anne-Sophie, additional, Le Pointe, Hubert Ducou, additional, Duranteau, Lise, additional, Fakhouri, Fadi, additional, Fernandez, Hervé, additional, Ferrand, Hélène, additional, Filippova, Julia, additional, Fior, Renato, additional, Frank, Michael, additional, Friedman, Diane, additional, Galacteros, Frédéric, additional, Gallot, Denis, additional, Garcia, Gilles, additional, Gauvrit, Jean-Yves, additional, Gervais, Anne, additional, Girot, Robert, additional, Godeau, Bertrand, additional, Grangé, Gilles, additional, Grenet, Dominique, additional, Groussin, Lionel, additional, Guettrot-Imbert, Gaëlle, additional, Habibi, Anoosha, additional, Hadj-Rabia, Smail, additional, Hermine, Olivier, additional, Houfflin-Debarge, Véronique, additional, Houyel, Lucile, additional, Hugon-Rodin, Justine, additional, Humbert, Marc, additional, Iserin, Laurence, additional, Iung, Bernard, additional, Jaïs, Xavier, additional, Joly, Bérangère, additional, Jondeau, Guillaume, additional, Kahn, Jean-Emmanuel, additional, Kayem, Gilles, additional, Keita, Hawa, additional, Keller, Valentin, additional, Ladouceur, Magalie, additional, Legardeur, Hélène, additional, Le Guern, Véronique, additional, Lejeune, Claude, additional, Le Jeunne, Claire, additional, Le Ray, Camille, additional, Luton, Dominique, additional, Manamani-Bererhi, Lynda, additional, Mandelbrot, Laurent, additional, Marie, Isabelle, additional, Matheron, Sophie, additional, Maulard, Amandine, additional, Merbai, Nadia, additional, Messas, Emmanuel, additional, De Miranda, Sandra, additional, Morgant, Stéphanie, additional, Msika, Simon, additional, Nebout, Sophie, additional, Nedellec, Sophie, additional, Nizard, Jacky, additional, d'Oiron, Roseline, additional, Ozenne, Violaine, additional, Perlemuter, Gabriel, additional, Perrouin-Verbe, Brigitte, additional, Perrotin, Franck, additional, Peynaud-Debayle, Edith, additional, Philippe, Henri-Jean, additional, Picard, Clément, additional, Picone, Olivier, additional, Pigeyre, Marie, additional, Plouin, Pierre-François, additional, Plu-Bureau, Geneviève, additional, Polivka, Laura, additional, Poulain, Patrice, additional, de Pradier, Marie, additional, Raccah-Tebeka, Brigitte, additional, Ribeil, Jean-Antoine, additional, Rouzier, Roman, additional, Ronziere, Thomas, additional, Rossi, Aude, additional, Saadoun, David, additional, Selleret, Lise, additional, Sellier, Pierre, additional, Sénat, Marie-Victoire, additional, Subtil, Damine, additional, Taillé, Camille, additional, Therby, Denis, additional, Tô, Ngoc-Tram, additional, de Toffol, Bertrand, additional, Trillot, Nathalie, additional, Tsatsaris, Vassilis, additional, Tuyeras, Géraud, additional, Valentin, Morgane, additional, Vambergue, Anne, additional, Vandendriessche, David, additional, Verspyck, Eric, additional, Vincent-Rohfritsch, Aurélie, additional, Voltzenlogel, Marie-Catherine, additional, Vukusic, Sandra, additional, Wechsler, Bernard, additional, Winer, Norbert, additional, and Young, Jacques-François, additional

Published
2014
Full Text
View/download PDF

7. French national cohort of first use of dalbavancin: A high proportion of off-label use

Author

Dinh, Aurélien, primary, Duran, Clara, additional, Pavese, Patricia, additional, Khatchatourian, Lydie, additional, Monnin, Boris, additional, Bleibtreu, Alexandre, additional, Denis, Eric, additional, Etienne, Cédric, additional, Rouanes, Nicolas, additional, Mahieu, Rafael, additional, Bouchand, Frédérique, additional, Davido, Benjamin, additional, Lotte, Romain, additional, Cabaret, Philippe, additional, Camou, Fabrice, additional, Chavanet, Pascal, additional, Assi, Assi, additional, Limonta, Silvia, additional, Lechiche, Catherine, additional, Riou, Raphaëlle, additional, Courjon, Johan, additional, Illes, Gabriela, additional, Lacassin-Beller, Flore, additional, Senneville, Eric, additional, Adjodah, Chandra, additional, Baclet, Nicolas, additional, Bouchard, Odile, additional, Boutoille, David, additional, Brunin, Guillaume, additional, Carbognani, Daniel, additional, Delobel, Pierre, additional, Ferrand, Hélène, additional, Imbert, Yves, additional, Leautez-Nainville, Sophie, additional, Le Moing, Vincent, additional, Loutfi, Bouchra, additional, Mrozek, Natacha, additional, Rouzic, Nicolas, additional, Talarmin, Jean-Philippe, additional, Tattevin, Pierre, additional, and Weyrich, Pierre, additional

Published
2019
Full Text
View/download PDF

9. Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis.

Author

Pantel, Alix, Petrella, Stéphanie, Veziris, Nicolas, Matrat, Stéphanie, Bouige, Aurélie, Ferrand, Hélène, Sougakoff, Wladimir, Mayer, Claudine, and Aubry, Alexandra

Subjects
DRUG resistance, FLUOROQUINOLONES, MYCOBACTERIUM tuberculosis, GENETIC mutation, DNA topoisomerase II, DISEASE susceptibility, ANTITUBERCULAR agents, DRUG resistance in microorganisms, ENZYMES, ESCHERICHIA coli, MICROBIAL sensitivity tests, QUINOLONE antibacterial agents, RECOMBINANT proteins, SEQUENCE analysis, PHARMACODYNAMICS
Abstract

Objectives: Resistance to fluoroquinolones (FQs) in Mycobacterium tuberculosis (Mtb) is mainly due to mutations in DNA gyrase (GyrA2B2), with the most common substitutions located at positions 90 and 94 in GyrA. Two clinical MDR Mtb (MDR-TB) strains harbouring an A90E or D94N substitution in GyrA were found to be surprisingly susceptible to FQs (ofloxacin MIC ≤2 mg/L). We studied the impact of the additional GyrA substitutions found in these strains (T80A and T80A + A90G, respectively) on FQ susceptibility.Methods: Mutants of interest were generated by site-specific mutagenesis of GyrA alleles. WT and mutant TB DNA gyrase subunits were overexpressed in Escherichia coli and purified, and the in vitro susceptibility to FQs of their DNA supercoiling reaction was studied.Results: IC50s of mutant gyrase complexes bearing GyrA D94N and A90E were 3- to 36-fold higher than WT IC50s, whereas IC50s of gyrase bearing T80A + A90G + D94N and T80A + A90E were close to the WT IC50s.Conclusions: We demonstrated that substitutions T80A and A90G restore FQ susceptibility when associated with a substitution implicated in high-level FQ resistance. Line probe assay misclassification of MDR-TB strains as pre-XDR or XDR can be corrected by sequence analysis of gyrA. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

10. La lampe allumée... / [Hélène Ferrand]

Author

Ferrand, Hélène. Auteur du texte and Ferrand, Hélène. Auteur du texte

Abstract

Collection : Caractères ; 39, Collection : Caractères ; 39, Contient une table des matières, Avec mode texte

Published
1971

11. Time to Treatment Initiation and HIV Viral Suppression in People Diagnosed With HIV-1 During COVID-19 Pandemic in Ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study).

Author

Ben Farhat J, Hessamfar M, Farbos S, Desclaux A, Dumondin G, Ferrand H, Greib C, Castan B, Rispal P, Duffau P, Leleux O, Perrier A, Wittkop L, Bonnet F, and Barger D

Subjects
Adult, Humans, Pandemics, Time-to-Treatment, Viral Load, HIV Infections drug therapy, HIV Infections epidemiology, HIV Infections diagnosis, HIV-1, COVID-19 epidemiology, HIV Seropositivity drug therapy, Anti-HIV Agents therapeutic use
Abstract

Objectives: The COVID-19 pandemic's impact on initiation and effectiveness of antiretroviral therapy (ART) in people diagnosed with HIV remains unclear. We evaluated critical delays in HIV care in people diagnosed before and during the pandemic in ex-Aquitaine, France., Methods: We considered adults diagnosed with HIV-1 in 2018-2021 and enrolled in the ANRS CO3 AQUIVIH-NA and followed them until October 10, 2022 for those diagnosed during the pandemic (April 01, 2020-December 31, 2021) and until March 31, 2020 for historical controls. We compared their characteristics at inclusion and the median time between diagnosis and ART initiation, ART initiation and viral suppression, and diagnosis and virologic, suppression (effective management)., Results: Eighty-three individuals were diagnosed during the pandemic versus 188 during the prepandemic period. Median follow-up was 549 (interquartile range: 329-713) days. Populations were similar in sex, age, HIV acquisition mode, hospital type, and clinical characteristics at diagnosis; however, fewer were foreign-born during the pandemic (15.7% versus 33.5%, P = 0.003). The probability of ART initiation, therapeutic success, and effective management was higher in people living with HIV (PLWH) diagnosed during the pandemic in adjusted analyses (hazard ratio [HR]: 2.0; 95% CI: 1.5 to 2.7; HR: 1.7; 95% CI: 1.2 to 2.3; HR: 1.8; 95% CI: 1.3 to 2.6, respectively). Those diagnosed during the pandemic were 2.3 (95% CI: 1.2 to 4.1) times more likely to be virologically suppressed within six months of diagnosis compared with historical controls., Conclusions: Pandemic-related reorganizations may have resulted in newly diagnosed PLWH being prioritized; however, the lower proportion of foreign-born PLWH diagnosed during the pandemic period, likely because of reduced migration and potential delays in diagnosis, may contribute to these preliminary findings., Competing Interests: The authors declare no conflicts of interest in relation to this manuscript. S.F. has received financial support from Gilead Sciences, MSD and ViiV Healthcare to attend scientific conferences. D.B. has received speaking fees from Gilead Healthcare, MSD, ViiV Healthcare and outside the submitted work., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

12. Listeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia.

Author

Ferrand H, Tamburini J, Mouly S, Bouscary D, and Bergmann JF

Subjects
Anti-Bacterial Agents therapeutic use, Benzamides, Female, Humans, Imatinib Mesylate, Meningitis, Listeria drug therapy, Middle Aged, Monocytes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive complications, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukopenia chemically induced, Leukopenia complications, Meningitis, Listeria complications, Piperazines adverse effects, Piperazines therapeutic use, Pyrimidines adverse effects, Pyrimidines therapeutic use
Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results